Roche Holding AG (RHHBF)
USD 303.32
(0.0%)
USD 303.32
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 14.31 CHF | -7.34% |
| 2022 | 15.53 CHF | -5.25% |
| 2021 | 16.39 CHF | -1.97% |
| 2020 | 16.72 CHF | 6.02% |
| 2019 | 15.77 CHF | 28.21% |
| 2018 | 12.30 CHF | 21.54% |
| 2017 | 10.12 CHF | -9.96% |
| 2016 | 11.24 CHF | 7.87% |
| 2015 | 10.42 CHF | -5.19% |
| 2014 | 10.99 CHF | -16.49% |
| 2013 | 13.16 CHF | 18.35% |
| 2012 | 11.12 CHF | 1.0% |
| 2011 | 11.01 CHF | 8.58% |
| 2010 | 10.14 CHF | 11.8% |
| 2009 | 9.07 CHF | -13.04% |
| 2008 | 10.43 CHF | -8.19% |
| 2007 | 11.36 CHF | 22.94% |
| 2006 | 9.24 CHF | 31.81% |
| 2005 | 7.01 CHF | -10.81% |
| 2004 | 7.86 CHF | 114.75% |
| 2003 | 3.66 CHF | 176.25% |
| 2002 | -4.80 CHF | -209.09% |
| 2001 | 4.40 CHF | -57.24% |
| 2000 | 10.29 CHF | 54.04% |
| 1999 | 6.68 CHF | 31.24% |
| 1998 | 5.09 CHF | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 3.90 CHF | 0.0% |
| 2024 Q1 | 3.90 CHF | -28.7% |
| 2023 FY | - CHF | -7.34% |
| 2023 Q3 | 2.72 CHF | -69.54% |
| 2023 Q4 | 5.47 CHF | 101.1% |
| 2023 Q2 | 8.93 CHF | 101.13% |
| 2023 Q1 | 4.44 CHF | -8.83% |
| 2022 FY | - CHF | -5.25% |
| 2022 Q4 | 4.87 CHF | 102.07% |
| 2022 Q1 | 5.27 CHF | -27.31% |
| 2022 Q2 | 10.54 CHF | 100.0% |
| 2022 Q3 | 2.41 CHF | -77.13% |
| 2021 Q1 | 4.53 CHF | -37.69% |
| 2021 FY | - CHF | -1.97% |
| 2021 Q3 | 3.57 CHF | -60.94% |
| 2021 Q4 | 7.25 CHF | 103.08% |
| 2021 Q2 | 9.14 CHF | 101.77% |
| 2020 FY | - CHF | 6.02% |
| 2020 Q1 | 4.66 CHF | -18.25% |
| 2020 Q2 | 9.45 CHF | 102.79% |
| 2020 Q3 | 3.60 CHF | -61.9% |
| 2020 Q4 | 7.27 CHF | 101.94% |
| 2019 Q4 | 5.70 CHF | 102.13% |
| 2019 Q1 | 4.99 CHF | 169.73% |
| 2019 Q2 | 4.99 CHF | 0.0% |
| 2019 FY | - CHF | 28.21% |
| 2019 Q3 | 2.82 CHF | -43.49% |
| 2018 Q1 | 4.25 CHF | 132.24% |
| 2018 FY | - CHF | 21.54% |
| 2018 Q4 | 1.85 CHF | 0.0% |
| 2018 Q3 | 1.85 CHF | -56.47% |
| 2018 Q2 | 4.25 CHF | 0.0% |
| 2017 Q2 | 3.19 CHF | 0.0% |
| 2017 Q1 | 3.19 CHF | 30.2% |
| 2017 FY | - CHF | -9.96% |
| 2017 Q4 | 1.83 CHF | 0.0% |
| 2017 Q3 | 1.83 CHF | -42.63% |
| 2016 Q1 | 3.12 CHF | 45.12% |
| 2016 FY | - CHF | 7.87% |
| 2016 Q2 | 3.12 CHF | 0.0% |
| 2016 Q4 | 2.45 CHF | 0.0% |
| 2016 Q3 | 2.45 CHF | -21.47% |
| 2015 FY | - CHF | -5.19% |
| 2015 Q1 | 2.99 CHF | 35.91% |
| 2015 Q4 | 2.15 CHF | 0.0% |
| 2015 Q3 | 2.15 CHF | -28.09% |
| 2015 Q2 | 2.99 CHF | 0.0% |
| 2014 Q3 | 2.20 CHF | -31.25% |
| 2014 FY | - CHF | -16.49% |
| 2014 Q4 | 2.20 CHF | 0.0% |
| 2014 Q2 | 3.20 CHF | -0.31% |
| 2014 Q1 | 3.21 CHF | 5.94% |
| 2013 FY | - CHF | 18.35% |
| 2013 Q2 | 3.44 CHF | 0.0% |
| 2013 Q3 | 3.03 CHF | -11.92% |
| 2013 Q4 | 3.03 CHF | 0.0% |
| 2013 Q1 | 3.44 CHF | 0.0% |
| 2012 FY | - CHF | 1.0% |
| 2011 FY | - CHF | 8.58% |
| 2010 FY | - CHF | 11.8% |
| 2009 FY | - CHF | -13.04% |
| 2008 FY | - CHF | -8.19% |
| 2007 FY | - CHF | 22.94% |
| 2006 FY | - CHF | 31.81% |
| 2005 FY | - CHF | -10.81% |
| 2004 FY | - CHF | 114.75% |
| 2003 FY | - CHF | 176.25% |
| 2002 FY | - CHF | -209.09% |
| 2001 FY | - CHF | -57.24% |
| 2000 FY | - CHF | 54.04% |
| 1999 FY | - CHF | 31.24% |
| 1998 FY | - CHF | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AstraZeneca PLC | 3.84 USD | -272.656% |
| Bristol-Myers Squibb Company PFD CONV 2 | 3.88 USD | -268.814% |
| CSPC Pharmaceutical Group Limited | 0.07 USD | -20342.857% |
| Clarus Therapeutics Holdings, Inc. | -8.04 USD | 277.985% |
| Novartis AG | 7.63 USD | -87.549% |
| PT Kalbe Farma Tbk. | 0.00 USD | -366823.077% |